Essential Thrombocythaemia
Essential thrombocythaemia (ET) is a blood disorder where the body produces too many platelets, which can lead to complications such as blood clots or bleeding issues.
High-Risk Essential Thrombocythaemia: STP938 Treatment Study
We are evaluating a new medication for adults with high-risk essential thrombocythaemia who have not tolerated or responded to standard treatment. The study aims to assess its safety and early effects.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hôpital Cavale Blanche CHU de Brest
Institut de Cancérologie et d’Imagerie
Guilers, France
Institut Paoli Calmettes
Service d‘Onco-Hématologie
Marseille, France
Centre Hospitalier Universitaire De Nantes
Hématologie Clinique
Nantes, France
Sponsor: Step Pharma
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.